Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$3.63 - $6.06 $117,176 - $195,616
-32,280 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$3.76 - $14.16 $121,372 - $457,084
32,280 New
32,280 $186,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $98M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Ostrum Asset Management Portfolio

Follow Ostrum Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ostrum Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Ostrum Asset Management with notifications on news.